Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Minneapolis, Minnesota 55455


A phase II trial of CD3/CD19 depleted, IL-15 activated, donor natural killer (NK) cells in adults and subcutaneous IL-15 given after a preparative regimen for the treatment of relapsed or refractory acute myelogenous leukemia (AML). The primary objective is to study the potential efficacy of NK cells and IL-15 to achieve complete remission while maintaining safety.


Inclusion Criteria (Recipient): - Meets ONE of the following disease criteria: 1. Primary AML induction failure: no CR after 2 or more induction attempts 2. Relapsed AML or Secondary AML (from MDS or treatment related): not in CR after 1 or more cycles of standard re-induction therapy 3. AML relapsed > 2 months after transplant: No re-induction required, and no more than 1 re-induction cycle is allowed. 4. Relapsed AML for patients > 60 years of age the 1 cycle of standard chemotherapy is not required if either of the following criteria is met: - Relapse within 6 months of last chemotherapy - BM blast count < 30% within 10 days of starting protocol therapy - Available related HLA-haploidentical donor (aged 14 to 75 years) by at least Class I serologic typing at the A&B locus - Karnofsky Performance Status ≥ 60% - Patients must have adequate organ within 14 days (28 days for pulmonary and cardiac) of study registration - Able to be off prednisone or other immunosuppressive medications for at least 3 days prior to NK cell infusion (excluding preparative regimen pre-medications). - Agrees to use contraception prior to study entry and for the duration of study participation. Exclusion Criteria (Recipient): - Bi-phenotypic acute leukemia. - Transplant < 60 days prior to study enrollment. - Active autoimmune disease. - History of severe asthma - Uncontrolled intercurrent illness - New or progressive pulmonary infiltrates on screening chest x-ray or chest CT scan that has not been evaluated with bronchoscopy - Pleural effusion large enough to be detectable on chest x-ray. - Pregnant women - History of HIV, active or chronic hepatitis B, hepatitis C or HTLV-I infection - Known hypersensitivity to any of the study agents used - Received investigational drugs within the 14 days of study registration. - Known active CNS involvement. Criteria For Initial Donor Selection: - Related donors (sibling, parent, offspring, parent or offspring of an HLA identical sibling). - 14-75 years of age. - At least 40 kilogram body weight. - In general good health as determined by the evaluating medical provider. - HLA-haploidentical donor/recipient match by at least Class I serologic typing at the A&B locus. - Not pregnant. - Able and willing to undergo apheresis.



Primary Contact:

Principal Investigator
Jeffrey Miller, MD
Masonic Cancer Center, University of Minnesota

Backup Contact:


Location Contact:

Minneapolis, Minnesota 55455
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source: ClinicalTrials.gov

Date Processed: November 18, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.